{"doi":"10.4269/ajtmh.2007.76.494","title":"TAFENOQUINE FOR THE TREATMENT OF RECURRENT PLASMODIUM VIVAX MALARIA","abstract":"<jats:p>Tafenoquine was used to treat <jats:italic>Plasmodium vivax</jats:italic> malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional <jats:italic>P. vivax</jats:italic> relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine-tolerant strains of <jats:italic>P. vivax</jats:italic> malaria.</jats:p>","journal":"The American Journal of Tropical Medicine and Hygiene","year":2007,"id":607703,"datarank":0.5570358100056463,"base_score":3.713572066704308,"endowment":3.713572066704308,"self_citation_contribution":0.5570358100056463,"citation_network_contribution":0.0,"self_endowment_contribution":0.5570358100056463,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":40,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1560506,"name":"PETER NASVELD","orcid":null,"position":1,"is_corresponding":false},{"id":1560507,"name":"MICHAEL D. EDSTEIN","orcid":null,"position":2,"is_corresponding":false},{"id":1560505,"name":"SCOTT KITCHENER","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"TAFENOQUINE FOR THE TREATMENT OF RECURRENT PLASMODIUM VIVAX MALARIA","abstract":"<jats:p>Tafenoquine was used to treat <jats:italic>Plasmodium vivax</jats:italic> malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional <jats:italic>P. vivax</jats:italic> relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine-tolerant strains of <jats:italic>P. vivax</jats:italic> malaria.</jats:p>","is_dataset_classified":null,"base_score":3.713572066704308,"endowment":3.713572066704308,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"17360873","pmcid":null,"openalex_id":"https://openalex.org/W1907847513","authors":[],"funders":[],"total_grants":0,"fwci":3.5236,"citation_percentile":0.91496144,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":3},{"year":2014,"count":1},{"year":2015,"count":2},{"year":2016,"count":5},{"year":2017,"count":2},{"year":2018,"count":1},{"year":2019,"count":3},{"year":2020,"count":3},{"year":2022,"count":2}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"http://www.ajtmh.org/deliver/fulltext/14761645/76/3/0760494.pdf?itemId=%2Fcontent%2Fjournals%2F10.4269%2Fajtmh.2007.76.494&mimeType=pdf&containerItemId=content/journals/14761645","host_type":"journal"},{"url":"http://www.ajtmh.org/deliver/fulltext/14761645/76/3/0760494.pdf?itemId=%2Fcontent%2Fjournals%2F10.4269%2Fajtmh.2007.76.494&mimeType=pdf&containerItemId=content/journals/14761645","host_type":"publisher"},{"url":"https://www.ajtmh.org/view/journals/tpmd/76/3/article-p494.xml","host_type":"publisher"},{"url":"https://www.ajtmh.org/downloadpdf/journals/tpmd/76/3/article-p494.xml","host_type":"publisher"},{"url":"https://doi.org/10.4269/ajtmh.2007.76.494","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/17360873","host_type":"repository"}],"fields_of_study":["Malaria Research and Control","Venomous Animal Envenomation and Studies","Infectious Encephalopathies and Encephalitis"],"mesh_terms":["Adult","Aminoquinolines","Antimalarials","Chloroquine","Humans","Recurrence","Malaria, Vivax"],"keywords":["Primaquine","Chloroquine","Plasmodium vivax","Malaria","Medicine","Vivax malaria","Pharmacology","Immunology","Plasmodium falciparum"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T06:52:07.352443Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}